BAT, BRCAness, and PARPi
# Does AR Inhibition Really Create BRCAness? Implications for BAT + Olaparib
I assumed it did and early evidence supported this. Because this is now in doubt I will reserve my PARPi use to SPA phases.
October 19, 2026
New evidence challenges the assumption that androgen receptor signaling inhibitors (ARSIs) reliably create BRCAness—a temporary impairment of homologous recombination repair (HRR) that sensitizes prostate cancer to PARP inhibitors (PARPi).
An October 2026 Nature Medicine randomized phase II trial found that enzalutamide suppressed HRR-related gene expression without demonstrating corresponding functional HRR impairment in paired tumor biopsies. Adding talazoparib increased grade ≥3 adverse events (68% versus 35%) without a statistically significant improvement in the primary PSA endpoint.
A separate 2026 PNAS study found that AR inhibition could actually reduce PARPi sensitivity in HRR-proficient prostate-cancer models by suppressing cell-cycle progression. However, other 2026 translational research found functional RAD51 suppression and increased PARPi sensitivity after ARSI exposure in selected patient-derived models.
Conclusion: ARSI-induced BRCAness is possible, but neither universal nor reliably predicted by reduced HRR gene expression.
## Why BAT + Olaparib May Work Without HRR Mutations
The phase II BAT–olaparib trial enrolled 36 men with metastatic castration-resistant prostate cancer and reported:
- PSA50 response: 31% at 12 weeks; 44% at any time.
- Median clinical/radiographic progression-free survival: 13 months.
- Responses in patients with and without identified HRR mutations.
The single-arm trial cannot establish how much benefit olaparib added to BAT alone. Nevertheless, its findings support investigating two mechanisms:
1. DNA-damage overload: Supraphysiologic androgen (SPA) induces AR/TOP2B-associated DNA breaks. Olaparib inhibits PARP-mediated repair and traps PARP complexes on DNA. The resulting damage and replication stress might overwhelm even functional HRR machinery.
2. Transient BRCAness: SPA itself may temporarily impair BRCA2/RAD51-associated repair, simultaneously increasing DNA damage and reducing repair capacity.
Both mechanisms could operate together. Neither necessarily requires an inherited or somatic HRR mutation.
## Could Intermittent Olaparib Reduce Toxicity?
The BAT–olaparib trial used continuous olaparib throughout each 28-day testosterone cycle. It did not establish that continuous exposure was necessary.
If SPA creates a temporary PARPi-sensitive state, concentrating olaparib around that window might reduce cumulative exposure while preserving some antitumor activity.
| Treatment window | Mechanistic rationale | Uncertainty |
|---|---|---|
| During SPA | AR/TOP2B-associated DNA damage plus PARP trapping | Strongest SPA-linked rationale |
| Immediately after SPA | Persistent DNA lesions, repair activity and replication stress | Potentially valuable; duration unknown |
| Later low-T period | Continued PARP inhibition of surviving cells | Incremental SPA-specific benefit uncertain |
The important qualification is that PARP trapping is partly replication-dependent. SPA or subsequent ARSI treatment that causes prolonged cell-cycle arrest could reduce rather than enhance olaparib sensitivity.
Consequently, SPA followed by ARSI is not automatically superior to SPA plus olaparib. The outcome may depend on whether ARSI impairs repair while preserving sufficient proliferation.
Shorter olaparib exposure would reduce total drug exposure, but proportional reductions in toxicity or preservation of efficacy have not been demonstrated.
## Revised Hypothesis
Two distinct mechanisms should be considered:
- Induced BRCAness: Functional HRR impairment creates PARPi sensitivity.
- Induced PARPi vulnerability: DNA-damage overload, replication stress and PARP trapping create sensitivity even when HRR remains functional.
SPA may produce either or both. ARSI may enhance these effects in some tumor states but antagonize them in others.
Functional HRR assays (RAD51 foci), DNA-damage markers (γH2AX/53BP1), and cell-cycle measurements (EdU/Ki-67) could help distinguish these mechanisms.
The key research question is whether olaparib concentrated during SPA and early recovery can preserve antitumor activity while reducing cumulative toxicity. That remains a plausible, untested clinical strategy—not an established dosing approach.
### References
1. Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer. Nature Medicine, October 2026.
https://www.nature.com/articles/s41591-026-04671-5
2. Traphagen et al. Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer. PNAS, 2026.
https://doi.org/10.1073/pnas.2515790122
3. Elsesy et al. Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. British Journal of Cancer, 2026.
https://www.nature.com/articles/s41416-026-03518-7
4. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Phase II study.